Drug review: Ibrutinib
Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refracto...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Saila: | Indian Journal of Medical and Paediatric Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=3;spage=383;epage=392;aulast= |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|